Prognosis and monitoring of membranous nephropathy based on the analysis of PLA2R1 epitope profile and spreading

1. A method for monitoring the effectiveness of a treatment of membranous nephropathy or idiopathic membranous nephropathy in a human subject, comprising:

obtaining at a first time point a first body fluid sample selected from the group consisting of blood, serum and plasma;

detecting in vitro a first level of at least one, two, or three autoantibodies selected from the group consisting of an autoantibody directed against cysteine-rich domain (CysR) of PLA2R1, an autoantibody directed against C-type lectin domain 1 (CTLD1) of PLA2R1, and an autoantibody directed against C-type lectin domain 7 (CTLD7) of PLA2R1, in said first body fluid sample obtained from said human subject at said first time point;

obtaining at a second time point a second body fluid sample selected from the group consisting of blood, serum and plasma, wherein said first body fluid sample and said second body fluid sample are from a same body fluid;

detecting in vitro a second level of said at least one, two, or three autoantibodies selected from the group consisting of an autoantibody directed against CysR of PLA2R1, an autoantibody directed against CTLD1 of PLA2R1, and an autoantibody directed against CTLD7 of PLA2R1, in said second body fluid sample obtained from said human subject at said second time point, and

comparing the first and second levels of autoantibodies, wherein:

absence, from the second body fluid sample obtained from the subject at the second time point, of detectable autoantibodies respectively directed against CTLD1 and CTLD7, or a decrease of the second level of autoantibodies respectively directed against either or both of CTLD1 and CTLD7 relative to the first level, indicates that the treatment being monitored is effective; and

continuing the treatment being monitored; or

presence, in the second body fluid sample obtained from the human subject at the second time point, of detectable autoantibodies directed against either or both of CTLD1 and CTLD7, or an increase in the second level of autoantibodies directed against either or both of CTLD1 and CTLD7 relative to the first level, indicates that the treatment being monitored is not effective; and

administering to the human subject at least one additional treatment selected from the group consisting of immunosuppression, kidney dialysis and kidney transplant when the treatment being monitored is determined to be not effective.

2. The method of claim 1 , wherein absence, from the second body fluid sample obtained from the human subject at the second time point, of detectable autoantibodies respectively directed against CysR, CTLD1 and CTLD7, or a decrease of the second levels of said autoantibodies relative to the respective first levels, indicates that the treatment being monitored is effective.

3. The method of claim 1 , wherein said treatment is immunosuppressive therapy selected from the group consisting of cyclosporin, tacrolimus, azathioprine, infliximab, omalizumab, daclizumab, adalimumab, eculizumab, efalizumab, natalizumab, omalizumab and rapamycin, cyclophosphamide, chlorambucil, and rituximab.

4. The method of claim 1 , wherein said treatment comprises symptomatic treatment that comprises renin-angiotensin system blockade.

5. A method for selecting and monitoring a treatment for a human subject suffering from membranous nephropathy or idiopathic membranous nephropathy, comprising:

administering a treatment to be monitored, comprising renin-angiotensisn system blockade and/or diuretics, wherein administration of the monitored treatment may begin before, during or after obtaining a first body fluid sample;

obtaining at a first time point the first body fluid sample selected from the group consisting of blood, serum and plasma;

detecting in vitro a first level of at least one autoantibody selected from the group consisting of an autoantibody directed against C-type lectin domain 1 (CTLD1) of PLA2R1, and an autoantibody directed against C-type lectin domain 7 (CTLD7) of PLA2R1, in the first body fluid sample;

obtaining at a second time point a second body fluid sample selected from the group consisting of blood, serum and plasma, wherein said first body fluid sample and said second body fluid sample are from a same body fluid;

detecting in vitro a second level of said at least one autoantibody selected from the group consisting of an autoantibody directed against CTLD1 of PLA2R1, and an autoantibody directed against CTLD7 of PLA2R1 in the second body fluid sample, and

comparing the first and second levels of the at least one autoantibody, wherein:

detecting an absence of the at least one autoantibody in the second body fluid sample directed against either or both of CTLD1 and CTLD7, or a decrease of the second level of the at least one autoantibody directed against either of CTLD1 and CTLD7 relative to the first level indicates that the monitored treatment is effective; and

continuing administration of the monitored treatment without immunosuppression or hemodialysis; or

detecting a presence of the at least one autoantibody in the second body fluid sample directed against either or both of CTLD1 and CTLD7, or an increase in the second level of the at least one autoantibody directed against either or both of CTLD1 and CTLD7 relative to the first level indicates that the monitored treatment is not effective; and

administering at least one additional treatment to the patient selected from the group consisting of immunosuppression, kidney dialysis and kidney transplant.

6. The method of claim 5 , wherein the detecting steps are performed using an assay selected from the group consisting of agglutination test, enzyme-labeled immunoassay, ELISA, biotin/avidin assay, radioimmunoassay, immunoelectrophoresis, and immunoprecipitation.

7. The method of claim 5 , wherein the detecting steps are performed by ELISA.